CAR T Therapy Breaks Into Autoimmune Frontier: First Patient Treated for Multiple Sclerosis

By

Breaking: A groundbreaking cancer treatment is now targeting autoimmune diseases, with the first multiple sclerosis patient enrolled in a clinical trial at the University of Nebraska Medical Center. The therapy, known as CAR T cell therapy, has already shown remarkable success in blood cancers and is now being tested in over 200 trials for conditions like lupus, Graves' disease, and vasculitis.

Jan Janisch-Hanzlik, 49, of Blair, Nebraska, became the first participant in the MS trial after her condition worsened despite standard medications. "I was afraid to carry my grandchildren because of frequent falls," she said. "I called the clinic every other month until they enrolled me." Her story highlights the urgent need for new options in autoimmune care.

Background

CAR T therapy works by reprogramming a patient's own immune cells to hunt and destroy specific targets. In cancer, those targets are malignant cells. In autoimmune diseases, the goal is to eliminate rogue immune cells that attack healthy tissue, essentially resetting the body's defenses to a pre-disease state.

The approach has shown promise in early studies for lupus and other conditions. Researchers believe it could offer a one-time treatment that halts disease progression, unlike current therapies that only manage symptoms. The Nebraska trial focuses on multiple sclerosis, a debilitating disease affecting over 2.8 million people worldwide.

What This Means

If successful, CAR T therapy could transform autoimmune treatment, offering a potential cure rather than lifelong management. Patients like Janisch-Hanzlik, who had to give up nursing and move to a wheelchair-accessible home, may regain their independence.

Experts caution that more data is needed. "We're optimistic but rigorous trials are essential," said Dr. James L. Neill, a lead investigator at the center. The next few years will determine whether CAR T becomes a standard option for millions of autoimmune patients globally.

For Janisch-Hanzlik, the trial represents hope. "I want to carry my grandchildren again without fear," she said. Her journey could redefine the boundaries of cellular therapy.

Related Articles

• How to Use Kin Health's AI Notetaker for Your Next Doctor Visit
• Appeals Court Imposes In-Person Rule for Abortion Pill Mifepristone
• FDA Drug Center Director Fired, Creating Leadership Crisis at Agency
• How to Trigger Your Brain's Natural Cleaning System with Simple Movements
• From Memes to Movement: A Practical Guide to Understanding and Resisting the Corporatization of Medicine
• 5 Key Insights from the 2025 PatientView Report on Pharma Reputation
• Genomics Revolutionary J. Craig Venter Dies at 79, Leaving a Legacy of Breakthroughs and Controversy
• The Unsettled Science Behind Youth Social Media Bans: A Closer Look at the Evidence